Principles of therapeutic apheresis in neurological disease
E Strasser - Transfusion Medicine and Hemotherapy, 2023 - karger.com
Background: Therapeutic plasma exchange (TPE) is a well-known apheresis technology
since many years and is available worldwide. Myasthenia gravis is one of the first …
since many years and is available worldwide. Myasthenia gravis is one of the first …
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre …
JA Allen, J Lin, I Basta, T Dysgaard, C Eggers… - The Lancet …, 2024 - thelancet.com
Background Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an
autoimmune disease of the peripheral nervous system that can lead to severe disability from …
autoimmune disease of the peripheral nervous system that can lead to severe disability from …
Chronic inflammatory demyelinating polyradiculoneuropathy: Five new things
C Karam - Neurology: Clinical Practice, 2022 - AAN Enterprises
Purpose of Review The purpose of this review is to give an update on chronic inflammatory
demyelinating polyradiculoneuropathy (CIDP). Recent findings There are several recent …
demyelinating polyradiculoneuropathy (CIDP). Recent findings There are several recent …
Utility of a pediatric adaptive sports clinic: a case series review
B Taib, Y Ma, R Tandon, R Knight… - … Therapy in Pediatrics, 2023 - Taylor & Francis
Background Limited funding is available for athletes with disabilities in the United Kingdom.
This compounds the barriers to participation and development that already exist. Method To …
This compounds the barriers to participation and development that already exist. Method To …
[HTML][HTML] Therapeutic Outcomes and Electrophysiological Biomarkers in Anti-Myelin-Associated Glycoprotein Neuropathy: a Multicenter Cohort Study in South Korea
Background and Purpose Unlike other immune-mediated neuropathies, anti-myelin-
associated glycoprotein (MAG) neuropathy is often refractory to immunotherapy. It is …
associated glycoprotein (MAG) neuropathy is often refractory to immunotherapy. It is …
[HTML][HTML] Serum B-cell activating factor is not a potential biomarker for disease activity in chronic inflammatory demyelinating polyneuropathy
MR Michael, L Wieske, MJ Koel-Simmelink… - Journal of …, 2023 - Elsevier
B-cell activating factor (BAFF) is a crucial cytokine for differentiation and survival of B-cells
and correlates to disease activity in some auto-immune diseases. To evaluate BAFF as a …
and correlates to disease activity in some auto-immune diseases. To evaluate BAFF as a …
Chronic inflammatory demyelinating polyradiculoneuropathy: Diagnostic problems in clinical practice in Serbia
I Basta, N Delic, I Gunjic… - Journal of the …, 2023 - Wiley Online Library
Making diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is
challenging since it can mimic a multitude of disorders, and is misdiagnosed in at least 50 …
challenging since it can mimic a multitude of disorders, and is misdiagnosed in at least 50 …
Determinants of long‐term disability in chronic inflammatory demyelinating polyradiculoneuropathy: A multicenter Korea/UK study of 144 patients
Background Despite standard‐of‐care treatment, therapeutic outcomes in chronic
inflammatory demyelinating polyradiculoneuropathy (CIDP) are often incomplete. We aimed …
inflammatory demyelinating polyradiculoneuropathy (CIDP) are often incomplete. We aimed …
A rare presentation of acute-onset chronic inflammatory demyelinating polyneuropathy with the detection of anti-GM3 and anti-sulfatides antibodies: a case report
R Sun, Y Meng, L Li, W Chen, J Xu, P Lv… - Frontiers in …, 2024 - frontiersin.org
Objectives Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired
immune-mediated neuropathy defined by clinical progression for more than 2 months. 16 …
immune-mediated neuropathy defined by clinical progression for more than 2 months. 16 …
Beneficial effects and safety of traditional Chinese medicine for chronic inflammatory demyelinating polyradiculoneuropathy: A case report and literature review
Y Xie, L Li, L Xie, J Jiang, T Yao, G Mao… - Frontiers in …, 2023 - frontiersin.org
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune-mediated
neuropathy. First-line treatments for CIDP include corticosteroids, intravenous …
neuropathy. First-line treatments for CIDP include corticosteroids, intravenous …